Key facts
- It has raised $9.1M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Y Combinator, Creative Destruction Lab, Pioneer Fund, Gaingels, National Institutes of Health — 29 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 29 names
- ·Watchlist + deal alerts for CatenaBio
- ·The full record, as it builds
Funding rounds
No funding rounds for CatenaBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CatenaBio
Developer of antibody-drug conjugates designed for the treatment of multiple diseases. The company's conjugates use protein conjugation technology that allows the attachment of any two proteins together quickly and more selectively than any competing method by attaching the natural amino acids tyrosine and cysteine, enabling researchers to create novel therapeutics in autoimmune disorders, oncology and vaccine development.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2020
- Employees
- 10
- Website
- catenabio.com/
- Ownership
- Privately Held (backing)
CatenaBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CatenaBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CatenaBio in its N-PORT filings yet. We sweep new filings monthly.